Macrophage Polarization: M1/M2 Markers, CSF1R & TREM2 (2026)
M1 vs M2 macrophage polarization in fibrosis: surface markers, flow cytometry panels, M2 subtypes (M2a/b/c), and targets like CSF1R inhibitors and TREM2.
Introduction: The Duality of Macrophages in Fibrosis
Macrophages are not simply cells that phagocytose pathogens. They possess remarkable plasticity — the ability to dramatically change their functional phenotype in response to microenvironmental cues. This makes them central commanders directing every phase of tissue pathology: from initial destruction (inflammation), through repair (fibrosis), to healing (fibrosis resolution).
In fibrosis research, understanding macrophage polarization — the dynamic balance between pro-inflammatory M1 and pro-fibrotic M2 phenotypes — is essential for both understanding disease progression and developing targeted therapeutics. This guide provides a comprehensive overview of the M1/M2 paradigm, M2 subtypes, key markers for experimental identification, and the latest therapeutic strategies.
1. M1 Macrophages: Pro-inflammatory Initiators
Activation Signals
- LPS (Lipopolysaccharide): Bacterial cell wall component (via TLR4)
- IFN-γ (Interferon-gamma): Th1 cell-derived cytokine (via IFNGR/JAK-STAT1)
- GM-CSF: Granulocyte-macrophage colony-stimulating factor
Key Functions
M1 macrophages appear immediately after tissue injury and initiate the acute inflammatory response:
- Pro-inflammatory cytokine release: Massive production of TNF-α, IL-1β, IL-6, and IL-12, recruiting neutrophils and monocytes to the injury site.
- Bactericidal activity: Generate Reactive Oxygen Species (ROS) and Nitric Oxide (NO) via iNOS to eliminate pathogens.
- ECM degradation: Produce MMPs (Matrix Metalloproteinases), particularly MMP-9 and MMP-12, initiating early tissue remodeling.
- Antigen presentation: Upregulate MHC-II and co-stimulatory molecules, bridging innate and adaptive immunity.
M1 Surface Markers for Experimental Identification
| Marker | Method | Notes |
|---|---|---|
| CD86 | Flow cytometry, IHC | Co-stimulatory molecule; reliable M1 indicator |
| CD80 | Flow cytometry | Co-stimulatory; often paired with CD86 |
| iNOS (NOS2) | WB, qPCR, IHC | Functional marker for NO production |
| MHC-II (I-A/I-E) | Flow cytometry | Antigen presentation capacity |
| CD38 | Flow cytometry | Recently identified M1-specific surface marker |
Relationship with Fibrosis
M1 macrophages do not directly promote fibrosis. However, chronic or excessive M1 activation causes persistent tissue damage that continuously triggers the repair cascade — ultimately resulting in fibrosis as the "scar that never stops forming."
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. M2 Macrophages: Pro-fibrotic Repair Promoters
Activation Signals
- IL-4, IL-13: Th2 cell-derived cytokines (via IL-4Rα/STAT6)
- IL-10: Anti-inflammatory cytokine
- Glucocorticoids, M-CSF: Additional polarizing signals
Key Functions
As inflammation resolves, macrophages polarize toward the M2 phenotype to promote tissue repair:
- Anti-inflammatory action: Produce IL-10 and TGF-β to suppress acute inflammation.
- Tissue repair: Secrete PDGF and IGF-1 to promote cell proliferation and angiogenesis.
- Fibrosis promotion: This is the critical point — M2 macrophages are a major cellular source of TGF-β, the master cytokine that differentiates fibroblasts into myofibroblasts and powerfully induces collagen production.
- Arginase-1 activity: Converts L-arginine to L-ornithine (a proline precursor), directly fueling collagen biosynthesis.
M2 Surface Markers for Experimental Identification
| Marker | Method | Notes |
|---|---|---|
| CD206 (Mannose Receptor) | Flow cytometry, IHC | Most widely used M2 marker |
| CD163 | Flow cytometry, IHC | Scavenger receptor; strong M2 indicator |
| Arginase-1 (Arg1) | WB, qPCR, enzymatic assay | Functional marker; competes with iNOS for substrate |
| CD301 (MGL) | Flow cytometry | M2a-specific |
| Fizz1/RELMα | qPCR, IHC | Murine M2 marker (no direct human ortholog) |
| Ym1 (Chi3l3) | qPCR, ELISA | Murine-specific M2 marker |
M2 Subtypes: Not All M2 Are Created Equal
M2 macrophages are further subdivided into functionally distinct subtypes — an essential consideration when designing targeted therapies:
| Subtype | Inducing Signal | Key Cytokines / Effectors | Primary Role | Relevance to Fibrosis |
|---|---|---|---|---|
| M2a (Wound Healing) | IL-4, IL-13 | TGF-β↑↑, PDGF, Fibronectin | Tissue repair, ECM deposition | Most pro-fibrotic subtype |
| M2b (Regulatory) | Immune complexes + LPS | IL-10↑, TNF-α↑, IL-1β↑ | Immune regulation, Th2 promotion | Indirect — amplifies Th2 loop |
| M2c (Deactivating) | IL-10, Glucocorticoids | TGF-β, MMP-9↑, MERTK↑ | Efferocytosis, ECM remodeling | Resolution-promoting — degrades excess collagen |
| M2d (Tumor-associated) | TLR agonists + A2R | VEGF, IL-10 | Angiogenesis, immunosuppression | Relevant in fibrosis-to-cancer transition (e.g., HCC in MASH) |
3. The M1-to-M2 Switch: Normal Healing vs. Pathological Fibrosis
Normal Wound Healing (Self-Limiting)
- Immediately after injury (M1 dominant): Pathogen clearance, removal of necrotic tissue
- Repair phase (M2 dominant): Controlled M1→M2 switch; tissue regeneration with appropriate ECM deposition
- Resolution: M2 macrophages undergo apoptosis or emigrate; tissue returns to homeostasis
Pathological Fibrosis (Self-Perpetuating)
In fibrotic diseases, this switch mechanism is dysregulated1:
- Excessive/persistent M2 activation: Chronic injury (e.g., ongoing steatosis in MASH, repeated bleomycin exposure) or excessive Th2 cytokines maintain M2 dominance
- Never-ending repair loop: Persistent TGF-β release drives continuous myofibroblast activation and excessive collagen deposition
- Loss of resolution capacity: The normal emergence of Ly6C-low restorative macrophages is impaired, preventing ECM degradation
This understanding has profound implications for drug development: simply blocking all macrophages (or all M2 macrophages) would also eliminate the resolution pathway. Selective targeting is essential.
4. Fibrosis "Resolution" and Restorative Macrophages
Excitingly, macrophages are not only "cells that create fibrosis" — they are also "cells that can dissolve fibrosis." This duality is central to the concept of fibrosis reversibility.
In the recovery phase, a distinct population of Ly6C-low (restorative) macrophages emerges and:
- Secretes MMPs (particularly MMP-9, MMP-12, MMP-13) to degrade excess collagen
- Phagocytoses apoptotic myofibroblasts and cellular debris (efferocytosis)
- Produces pro-resolution lipid mediators (resolvins, maresins)
This has been elegantly demonstrated in the CCl4 liver fibrosis model, where cessation of CCl4 injury leads to spontaneous fibrosis resolution driven by these restorative macrophage populations1.
5. Experimental Assessment of Macrophage Polarization
How to Evaluate M1/M2 Balance in Preclinical Studies
Flow Cytometry Panel (Recommended)
A practical multi-color panel for murine fibrosis studies:
| Channel | Marker | Purpose |
|---|---|---|
| Lineage gate | CD45⁺ CD11b⁺ F4/80⁺ | Identify tissue macrophages |
| M1 markers | CD86, MHC-II, CD38 | M1 polarization status |
| M2 markers | CD206, CD163, CD301 | M2 polarization status |
| Recruitment | Ly6C (high vs low) | Inflammatory vs. restorative phenotype |
Immunohistochemistry (IHC)
- Dual staining for F4/80 (pan-macrophage) + CD206 (M2) or iNOS (M1) on serial sections
- Enables spatial assessment — where in the fibrotic lesion are M1 vs. M2 concentrated?
- Quantify using ImageJ digital analysis for objectivity
Multiplex Immunofluorescence (mIF)
- Simultaneously visualize collagen, α-SMA, and macrophage subtypes on a single slide
- Spatial analysis of macrophage phenotypes within the fibrotic niche
- See our detailed Multiplex IF Protocol for Fibrotic Tissue for step-by-step guidance
Gene Expression (qPCR / RNA-seq)
- M1 signature: Nos2, Tnf, Il1b, Il6, Cxcl10
- M2 signature: Arg1, Mrc1 (CD206), Chil3 (Ym1), Retnla (Fizz1), Tgfb1
- Ratio-based analysis (e.g., iNOS/Arg1 ratio) provides a quantitative M1/M2 index
6. Macrophages as Drug Targets: Latest Therapeutic Strategies
In recent fibrosis and MASH research, therapeutic strategies have evolved far beyond simple "anti-inflammatory" approaches. The focus is now on directly targeting specific macrophage receptors, metabolism, and polarization programs.
6.1 CSF1R (Colony-Stimulating Factor 1 Receptor) Inhibition
Blocking CSF1R signaling — vital for macrophage survival and proliferation — depletes the pathological macrophage pool in fibrotic tissues. This approach has demonstrated potent anti-fibrotic effects in preclinical models of:
- IPF (Idiopathic Pulmonary Fibrosis) — Bleomycin model
- MASH/NASH — Diet-induced models
- Kidney fibrosis — UUO model
6.2 TREM2 (Triggering Receptor Expressed on Myeloid Cells 2)
While famous for its role in Alzheimer's disease, TREM2 is highly expressed on Lipid-Associated Macrophages (LAMs) that accumulate in MASH livers. TREM2⁺ macrophages show a mixed phenotype with both protective (lipid handling, efferocytosis) and pro-fibrotic (TGF-β signaling) properties. Both agonist and antagonist strategies are under active investigation.
6.3 Macrophage Reprogramming (M2→M1/Resolution)
Drawing from tumor immunology insights, next-generation approaches aim to forcibly reprogram established pro-fibrotic M2 macrophages:
- CD47-SIRPα axis blockade: Anti-CD47 antibodies ("don't eat me" signal antagonists) enhance macrophage phagocytic clearance of senescent cells and fibrotic debris
- TLR agonists: Selective TLR7/8 stimulation can shift M2 macrophages toward an M1-like resolution phenotype
- Metabolic reprogramming: Targeting the M2-associated oxidative phosphorylation (OXPHOS) vs. M1-associated glycolysis switch
6.4 Galectin-3 Inhibitors
Galectin-3 (Mac-2) is a lectin highly expressed by activated macrophages in fibrotic tissues. It promotes both macrophage recruitment and M2 polarization. The lead inhibitor GB0139/TD139 was previously in clinical development for IPF, but the Phase 2b GALACTIC-1 trial (reported August 2023) failed to meet its primary endpoint (FVC decline), and Galecto subsequently discontinued GB0139 development in IPF and pivoted to severe liver diseases4. Galectin-3 itself remains a target of interest for fibrosis, with follow-on candidates and other indications continuing in development.
7. Conclusion
Macrophage polarization control represents one of the most promising frontiers in fibrosis therapy. The key insight is that precision is required — not simply destroying all macrophages, but selectively suppressing "bad M2" (pro-fibrotic M2a) while preserving or enhancing "good" macrophages (restorative Ly6C-low, M2c) that drive fibrosis resolution.
By combining robust preclinical fibrosis models with systematic M1/M2 phenotyping via flow cytometry, IHC, and transcriptomics, researchers can capture the true in vivo efficacy of these novel targeted therapeutics and make informed Go/No-Go decisions.
References & Clinical Trial Info
1. Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity. 2016;44(3):450-462. PubMed
2. Murray PJ, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14-20. PubMed
3. Sica A, et al. Macrophage polarization in pathology. Cell Mol Life Sci. 2015;72(21):4111-4126. PubMed
4. MacKinnon AC, et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012;185(5):537-546. PubMed
Related Articles
- Fibroblasts and Myofibroblasts: The Effector Cells of Fibrosis
- Inflammation and Fibrosis: Understanding the Mechanistic Link
- TGF-β/Smad Signaling Pathway in Fibrosis
- Comprehensive Guide to Fibrosis Quantification Methods
- Quantifying IHC with ImageJ: A Practical Guide
- Multiplex IF Protocol for Fibrotic Tissue Analysis